Biotech | May 01, 2022
Inmagene receives USFDA's IND clearance for ox40 antagonist
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)
Covaxin was earlier approved for children 12-18 years of age
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
The peptide-based vaccine induces a t cell-dependent response
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
Subscribe To Our Newsletter & Stay Updated
